$0of $10,000
UK Biobank secondary analysis testing whether metformin users show better glymphatic (DTI-ALPS), white-matter, abdominal MRI, metabolomic, and cognitive phenotypes vs propensity-matched non-users, with mediation linking body-brain-cognition. Fits the RFP's cognitive track; novel multimodal integration is a highlight, but observational cross-sectional design, confounding by indication, and an implausibly small budget limit enhancement claims.